- Sector: Healthcare
- Region: South East
Oxford Biomedica is a pioneer of gene and cell therapy. The company has played a critical role in developing this area of science, which is now widely recognised as the future of healthcare. Oxford Biomedica focuses on developing life-changing, potentially curative treatments for serious diseases and has built a sector-leading lentiviral vector delivery system, the LentiVector® platform.
Through the COVID-19 pandemic, Oxford Biomedica has had key worker status, which has allowed it to continue providing services to its healthcare customers. “The agility and dedication demonstrated by our workforce is recognised as a key strength of our business and has helped us manage the challenges associated with COVID-19 and lockdown,” says John Dawson, CEO of Oxford Biomedica.
The company is the lead manufacturer of a potential COVID-19 vaccine that’s being developed by AstraZeneca. It has signed an 18-month supply agreement to produce AstraZeneca’s AZD1222 vaccine on a commercial scale. “During the COVID-19 pandemic, we cemented our position as a leading gene and cell therapy group and developed working practices operationally at OxBox, our manufacturing facility, but also commercially by signing a number of new partnerships. This means we can carry on with business as normal if such a situation were to happen again,” John concludes.